Did You Know...
...that it was melting ice cream that inspired the invention of the outboard motor? It was a lovely August day and Ole Evinrude was rowing his boat to his favorite island picnic spot. As he rowed, he watched his ice cream melt and wished he had a faster way to get to the island. At that moment the idea for the outboard motor was born!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8076462 | Method for producing antithrombin composition The provision of an antithrombin composition having a desired α-form content rate or β-form content rate is required. The invention provides a process for producing an antithrombin composition having a desired α-form content rate or β-form content rate which is ... | 12/13/2011 |
| 7332577 | Therapeutic human albumin solutions with low prekallikrein activator (PKA) activity and process for obtaining them The invention discloses a purified albumin solution of human origin with low prekallicrein activator (PKA) activity and stability over time characterised in that it has an antithrombin content equal to or greater than 0.03 mg/g of albumin, and a process for producti... | 02/19/2008 |
| 7019193 | Treatments using transgenic goat produced antithrombin III This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acety... | 03/28/2006 |
| 7001993 | Human antithrombin variants Human antithrombin variants showing a high protease inhibitory activity even in the absence of heparin wherein at least one of the amino acids at positions 78, 278, 378 and 380 in the amino acid sequence of natural human antithrombin is substituted by another amino ... | 02/21/2006 |
| 6878813 | Human antithrombin IIIs and methods related thereto The present invention discloses modified antithrombin III compounds and methods. The amino acid compounds of the present invention are useful in treating blood clotting disorders, as well as other disease states associated with enzymes in the coagulation pathway. | 04/12/2005 |
| 6777541 | Protein purification II The present invention relates to a process for the preparation of a solution comprising a substantially pure isoform of AT-III, said process comprising separating the isoform AT-IIIα from AT-IIIβ on a calcium hydroxyphosphate-based adsorbent. ... | 08/17/2004 |
| 6518406 | Method for purification of proteins The present invention relates to methods for purification of antithrombin-III (AT-III) by precipitation of impurities. The said methods comprise (a) adding, to a solution comprising antithrombin-III, a saccharide and citrate, in an amount sufficient for i... | 02/11/2003 |
| 6491965 | Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates Novel conjugates of glycosaminoglycans, particularly heparin and dermatan sulfate, and amine containing species and therapeutic uses thereof are described. In particular, mild methods of conjugating heparins to proteins, such as antithrombin III and hepar... | 12/10/2002 |
| 6441145 | Transgenically produced Antithrombin III This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GaINAc) along with fuco... | 08/27/2002 |
| 6395880 | Method for purification of antithrombin III using an anion exchanger A method of purifying antithrombin III (AT III) from a starting material containing an AT III/heparin complex or an AT III/heparinoid complex is disclosed. First, the method comprises adsorbing the AT III/heparin complex or the AT III/heparinoid complex o... | 05/28/2002 |
| 6395881 | Separation of antithrombin III and ଲ variants by cyclodextrin-modified micellar electrokinetic chromatography A process is disclosed for the baseline separation of the and ଲ variants of antithrombin III AT-III. The process involves subjecting a sample comprising AT III to cyclodextrin-modified micellar electrokinetic chromatography (CD-MEKC). The CD... | 05/28/2002 |
| 6093804 | Method for purification of alpha-1 proteinase inhibitor The methods of the present invention provide a simple means for separating active and inactive Alpha Proteinase Inhibitor (API). The methods further provide means for purifying API at high yield (>70%), and at levels of purity (>90%) and activity (>90%) n... | 07/25/2000 |
| 5843705 | Transgenically produced antithrombin III This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GaINAc) along with fuco... | 12/01/1998 |
| 5817765 | Purification of plasma proteins Virus inactivating chemicals and/or detergents in an aqueous composition containing a water-soluble plasma protein are reduced by selecting a suitable combination of temperature and concentration above 0.5M of salt with a high salting out effect according... | 10/06/1998 |
| 5767108 | Method for making improved heparinized biomaterials A method of treating a patient with a medical device having immobilized heparin on a blood-contacting surface in which the covalently attached heparinized surface is provided with an adsorbed protein which may be activated by the immobilized heparin to bl... | 06/16/1998 |
| 5589516 | Liquid preparation of antithrombin-III and stabilizing method therefor A liquid preparation of antithrombin-III (AT-III), comprising an AT-III and an organic acid, a salt thereof, a sugar sulfate or a surfactant as a stabilizer, and a liquid preparation of AT-III, having a pH of 9-10. The preparation of the present invention... | 12/31/1996 |
| 5439802 | Method for determining the functional activity of free protein S or protein C in a plasma sample The present invention involves the determination of Protein S and Protein C activity in human plasma based on the addition of FIXa which indirectly influences the formation of thrombin.... | 08/08/1995 |
| 5420252 | Human antithrombin III mutants A novel human antithrombin III (AT III) mutant having a high antithrombin activity in the absence of heparin and effective in the treatment of thrombotic disorders as an anticoagulant, which is obtained by mutating amino acids at the reactive site and the... | 05/30/1995 |
| 5385890 | Antithrombin III preparation An antithrombin III is described comprising a lyophilized powder of antithrombin III and a polyoxyethylene glycol sorbitan alkyl ester as well as a kit composed of a container wherein a lyophilized powder of antithrombin III is placed and a solvent for th... | 01/31/1995 |
| 5319072 | Human antithrombin-III preparation A method for purifying human antithrombin III in an alcoholic solution at low temperature using bound heparin is provided.... | 06/07/1994 |
| 5252557 | Administration method of antithrombin An antithrombin solution for preventing fibrin formations, including antithrombin at a concentration of more than 0.5 U/ml and not more than 250 U/ml, a physiological buffer and optionally sodium hyaluronate. A related surgical method includes applying th... | 10/12/1993 |
| 5221614 | Method and reagent for determining the biological activity of antithrombin III by measuring coagulation time A method for determination of biological activity of AT III which comprises mixing a specimen, AT III free-extrinsic coagulation factor-containing plasma, heparin and a prothrombin time-measuring reagent or a factor X-activating reagent and then measuring... | 06/22/1993 |
| 5151266 | Use of anionic detergents with conjugates of monoclonal or polyclonal antibodies Methods are disclosed for increasing the solubility of antibodies and their radioisotope, toxin, or drug immunoconjugates and for reducing the non-specific uptake of antibody, either conjugated or unconjugated, into the RES organs such as via Fc receptor-... | 09/29/1992 |
| 5138034 | Method of fractionating plasma proteins A method of fractionating plasma protein which comprises treating a plasma protein-containing material in the following sequence of steps, provided that steps (ii) through (v) may be performed in an optional order: (i) freeze-thaw treatment, (ii) treatmen... | 08/11/1992 |
| 5093237 | Method and reagent for determining the biological activity of antithrombin III by measuring coagulation time A method for determination of biological activity of AT III by measuring coagulating time of blood plasma comprises mixing a specimen having AT III free-extrinsic coagulation factor-containing plasma, heparin and a prothrombin time-measuring reagent or a ... | 03/03/1992 |
| 5091177 | Monoclonal antibodies for treatment of human non-small cell lung carcinomas The present invention is concerned with novel monoclonal antibodies which define a glycolipid antigen associated with human non-small cell lung carcinomas ("NSCLC") and certain other human carcinomas. The antibodies bind to normal human cells to a much le... | 02/25/1992 |
| 5084273 | Composition of anticoagulants An anticoagulant containing as active ingredients protein C or activated protein C and heparin has a high anticoagulant activity which cannot be obtained with activated protein C or heparin alone. The activity of the anticoagulant is further increased by ... | 01/28/1992 |
| 5053492 | Immunopurification using monoclonal antibodies to Mojave toxin Monoclonal antibodies to Mojave toxin and use for isolation of cross-reacting proteins in Crotalus venoms are disclosed. Hybridomas secreting monoclonal antibodies against Mojave toxin were established. The antibodies were used for identifying cross-react... | 10/01/1991 |
| 4945054 | Process for the separation and purification of proteases and antiproteases of blood clotting, as well as of the protease/antiprotease complex The present invention relates to a process for separating and purifying proteases and antiproteases. This process is characterized in that there are placed in contact an insoluble cross-linked polymer including in its chain the group --SO3 R | 07/31/1990 |
| 4900720 | Replacement of human plasma using sterile solution of human plasma proteins excluding blood coagulation factors To maintain an almost unchanged plasma-protein profile in a patient subsequent to plasma exchange, the plasma-exchange medium contains the most essential human serum proteins, except for the coagulation factors, at a concentration of 75 g/l.... | 02/13/1990 |
| 4883784 | Human complement factors and their therapeutic use The administration of Factor I and/or Factor H to a mammal has been found to alleviate or prevent such autoimmune diseases as systemic lupus erythematosus, rheumatoid arthritis and glomerulonephritis.... | 11/28/1989 |
| 4841023 | Inactivation of viruses in labile protein-containing compositions using fatty acids There is disclosed a process for rendering a labile protein-containing composition, substantially free of lipid-containing viruses without incurring substantial protein denaturation comprising contacting said composition with an effective amount of a fatt... | 06/20/1989 |
| 4749783 | Viral inactivation and purification of active proteins Preparation of active therapeutic proteins comprising two essential steps. In the first step an active protein source is treated under conditions sufficient to inactivate any viruses present (e.g. via heat or chemical treatment). In the second step, the t... | 06/07/1988 |
| 4727027 | Photochemical decontamination treatment of whole blood or blood components Biological compositions are decontaminated by treatment with furocoumarin derivatives and irradiation under particular conditions in which the proteins retain their original physiological activities and any pathogenic microorganisms and polynucleotide fra... | 02/23/1988 |
| 4720385 | Protein compositions substantially free from infectious agents Compositions containing therapeutically or immunologically active proteins are rendered substantially free from infectious agents such as viable viruses and bacteria without substantial loss of therapeutic or immunologic activity by mixing the protein com... | 01/19/1988 |
| 4656254 | Method of preparing alpha-1-proteinase inhibitor and antithrombin III There is disclosed an improved method for separating one of alpha-1-proteinase inhibitor (also known as alpha-1 antitrypsin) and antithrombin-III from an aqueous solution of plasma proteins containing the same, such as from Cohn Fraction IV-1, Cohn Fracti... | 04/07/1987 |
| 4632981 | Human antithrombin III Human antithrombin III (AT III) as a product of genetically altered cell culture.... | 12/30/1986 |
| 4623717 | Pasteurized therapeutically active protein compositions Compositions containing thermally sensitive, therapeutically active proteins are pasteurized without substantial loss of therapeutic activity by mixing the protein composition with a pasteurization-stabilizing amount of a sugar or reduced sugar and of an ... | 11/18/1986 |
| 4623718 | Novel composition of matter of antithrombin III bound to a heparin fragment Novel chemical compounds which are heparin fragments with a molecular weight of from 2,000 to 5,500 covalently bound to antithrombin III, and their use in medicine.... | 11/18/1986 |
| 4540573 | Undenatured virus-free biologically active protein derivatives A mammalian blood protein-containing composition such as whole blood, plasma, serum, plasma concentrate, cryoprecipitate, cryosupernatant, plasma fractionation precipitate or plasma fractionation supernatant substantially free of hepatitis and other lipid... | 09/10/1985 |
